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Objectives This study sought to assess percutaneous coronary intervention (PCI) for unprotected left main coronary artery
(ULMCA) stenosis in routine U.S. clinical practice.
Background Percutaneous coronary intervention for ULMCA stenosis is controversial; however, current use and outcomes of
ULMCA PCI in routine U.S. clinical practice have not been described.
Methods We evaluated 5,627 patients undergoing ULMCA PCI at 693 centers within the National Cardiovascular Data Registry
Catheterization Percutaneous Coronary Intervention Registry for temporal trends in PCI use (2004 to 2008), patient
characteristics, and in-hospital mortality. Thirty-month mortality and composite major adverse events (death, myo-
cardial infarction, and revascularization) with drug-eluting versus bare-metal stents were compared using
inverse probability weighted (IPW) hazard ratios (HRs) in a nonrandomized Medicare-linked (age 65 years)
patient cohort (n  2,765).
Results ULMCA PCI was performed in 4.3% of patients with ULMCA stenosis. Unadjusted in-hospital mortality rates ranged
from 2.9% for elective cases to 45.1% for emergent/salvage cases. By 30 months, 57.9% of the elderly ULMCA PCI
population experienced death, myocardial infarction, or revascularization, and 42.7% died. Patients receiving drug-
eluting stents (versus bare-metal stents) had a lower 30-month mortality (IPW HR: 0.84, 95% confidence interval [CI]:
0.73 to 0.96), but the composite of major adverse events were similar (IPW HR: 0.95, 95% CI: 0.84 to 1.06).
Conclusions In the United States, ULMCA PCI is performed in 5% of patients with ULMCA disease and is generally reserved
for those at high procedural risk. Adverse events are common in elderly patients and are related to patient and
procedural characteristics, including stent type. (J Am Coll Cardiol 2012;59:648–54) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.883In the United States, revascularization of unprotected left
main coronary artery (ULMCA) stenosis has traditionally
been achieved with cardiac surgery. However, American
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February 14, 2012:648–54 Left Main PCIbypass grafting–eligible patients from a class III (i.e.,
“should not be performed”) to a Class IIb recommendation
(i.e., “may be considered”) (1) based on recent evidence (2).
Against this background, we examined trends in UL-
MCA PCI and long-term clinical outcomes in U.S. practice
using a Medicare-linked cohort from the NCDR (National
Cardiovascular Data Registry) CathPCI (Catheterization
Percutaneous Coronary Intervention) registry.
Methods
Study population. Analyses included all patients without a
prior history of coronary artery bypass graft surgery but with
a significant ULMCA stenosis at any of the 693 centers
with CathPCI registry participation between January 1,
2004, and December 31, 2008 (Fig. 1). A subgroup of
elderly patients with linkage to Medicare inpatient claims
was identified for longitudinal follow-up.
Follow-up information. To enable 30-month follow-up,
registry files were linked to Medicare 100% inpatient
fee-for-service claims, as previously described (3,4). The
Duke University School of Medicine Institutional Review
Board granted a waiver of informed consent and authoriza-
tion for this study.
Clinical endpoints. Primary endpoints included death and a
composite of major adverse events (i.e., death, myocardial
infarction, and repeat revascularization) and were assessed
using Medicare inpatient claims, as previously described (3).
tatistical analysis. Baseline patient and procedural charac-
eristics were summarized as counts and percentages for cate-
orical variables and mean with standard deviations for con-
inuous variables. The association of the ULMCA PCI rate
ith the year of index hospitalization was evaluated using a
hi-square test of trend. Statistical significance was defined as
p value 0.05. SAS statistical software (version 9.1, SAS
nstitute, Cary, North Carolina) was used for all calculations.
Propensity scores (including 107 covariates) (3) were used to
alance drug-eluting stents (DES) versus bare-metal stents
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nverse probability weighted esti-
ators incorporating the propen-
ity scores were used to balance
reatment groups (6).
For each of the primary end-
oints and within each of the pre-
pecified subgroups, cumulative
ncidence rates at 1, 12, and 30
onths were calculated using in-
erse probability weighted estima-
ors (7), and adjusted hazard ratios
HRs) and 95% confidence intervals (CIs) were calculated
ased on sandwich-estimated standard errors (8).
ubgroup analyses. High-urgency revascularization proce-
ures included primary PCI, rescue or facilitated PCI for
T-segment elevation myocardial infarction, or those involving
re-procedural cardiogenic shock, or emergent or salvage
tatus. Logistic EuroSCORE (European System for Cardiac
perative Risk Evaluation) values were calculated using the
ariable mapping algorithm in Online Table 1 and classified as
igh (33.5%) or low (33.5%) based on prior literature (9).
Figure 1 Population Flow Diagram
We began with a study population of 131,004 patients from 993 sites and,
after exclusions, ended with a final study population of 2,765 patients from
541 sites. CABG  coronary artery bypass graft; CathPCI  Catheterization
Percutaneous Coronary Intervention registry; CMS  Centers for Medicare &
Medicaid Services; FFS  fee for service; NCDR  National Cardiovascular
Data Registry; PCI  percutaneous coronary intervention; ULMCA  unpro-
tected left main coronary artery.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
PCI  percutaneous
coronary intervention
ULMCA  unprotected left
main coronary artery
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Left Main PCI February 14, 2012:648–54Intravascular ultrasound use was specific to the left main lesion,
but its timing (i.e., pre-PCI, post-PCI, or both) was
unspecified.
Sensitivity analyses. A post hoc “cause of death” analysis
was performed among patients surviving to hospital dis-
charge. Additionally, 2 sensitivity analyses were performed
to evaluate the potential influence of unmeasured confound-
Population Characteristics of All NCDRCathPCI Regist y Patient With ULMCA StenosisTable 1 Population Characteristics of All NCDRCathPCI Registry Patients With ULMCA Stenosis
Stented
(n  5,627)
Not Stented*
(n  125,377) p Value
Patient characteristics
Age, yrs 72.0 12.3 68.5 11.2 0.001
Male 3,349 (59.5%) 87,678 (69.9%) 0.001
Logistic EuroSCORE (high)† 752 (13.4%) 4,783 (3.8%)
Race/ethnicity
Caucasian 4,723 (84.0%) 104,344 (85.0%) 0.062
African American 264 (4.7%) 6,537 (5.3%) 0.041
Asian 127 (2.3%) 2,005 (1.6%) 0.001
Hispanic 198 (3.5%) 3,970 (3.2%) 0.229
Current smoking 1,003 (17.8%) 26,514 (23.5%) 0.001
CHF 4,563 (81.1%) 77,921 (69.0%) 0.001
HTN 4,488 (79.8%) 86,967 (77.1%) 0.001
Renal failure
No dialysis 481 (8.6%) 6,592 (5.3%) 0.001
Dialysis 251 (4.5%) 2,743 (2.2%) 0.001
Diabetes
Noninsulin-requiring 1,249 (22.2%) 26,503 (23.5%) 0.024
Insulin 755 (13.4%) 11,993 (10.6%) 0.001
Peripheral vascular disease 1,280 (22.8%) 19,188 (17.1%) 0.001
Stroke 1,160 (20.6%) 17,244 (15.3%) 0.001
Chronic lung disease 1,532 (27.2%) 21,705 (19.3%) 0.001
Prior PCI 1,707 (30.3%) 21,433 (17.1%) 0.001
Prior MI 1,852 (32.9%) 22,549 (20.1%) 0.001
Indication
Stable angina 797 (14.2%) 18,808 (15.0%) 0.084
UA 1,568 (27.9%) 37,273 (29.7%) 0.003
NSTEMI 1,396 (24.8%) 23,500 (18.7%) 0.001
STEMI 752 (13.4%) 11,727 (9.4%) 0.001
Pre-procedural shock 871 (15.5%) 4,306 (3.9%) 0.001
Pre-procedural IABP 360 (6.4%) 300 (0.3%) 0.001
Bifurcation lesion 1,812 (32.2%) 289 (0.23%) 0.0001
Hospital region
Northeast 908 (16.1%) 17,809 (14.2%) 0.001
South 1,618 (28.8%) 45,227 (36.2%) 0.001
Midwest 1,975 (35.1%) 40,790 (32.6%) 0.001
West 1,122 (20.0%) 21,228 (17.0%) 0.001
Hospital setting
Rural 465 (8.3%) 18,790 (15.0%) 0.001
Suburban 1,211 (21.5%) 34,039 (27.1%) 0.001
Urban 3,951 (70.2%) 72,548 (57.9%) 0.001
Values are mean  SD or n (%). *Patients “Not Stented” include those referred to coronary artery
ypass graft surgery and medically managed. †High logistic EuroSCORE defined as 33.5%.
CathPCI Catheterization Percutaneous Coronary Intervention registry; CHF congestive heart
ailure; EuroSCORE  European System for Cardiac Operative Risk Evaluation; HTN  hyperten-
ion; IABP  intra-aortic balloon pump; MI  myocardial infarction; NCDR  National Cardiovas-
cular Data Registry; NSTEMI non–ST-segment elevation myocardial infarction; PCI percutane-
us coronary intervention; STEMI  ST-segment elevation myocardial infarction; UA  unstable
angina; ULMCA  unprotected left main coronary artery.ers and treatment selection bias (Online Table 2).Results
Study population. From January 2004 to December 2008,
131,004 patients having 50% ULMCA stenosis were
included in the CathPCI registry (Fig. 1), with 4.3%
receiving ULMCA PCI. Compared with patients not
treated with PCI, stented patients were older with a higher
prevalence of both chronic comorbidities and acute pre-
procedural clinical instability (Table 1).
Of the 5,627 patients who underwent PCI for ULMCA
stenosis, 4,085 (72.6%) were 65 years of age, including
2,765 (69%) with successful linkage to Medicare inpatient
claims files (Fig. 1, Online Table 1). Medicare-linked
patients were largely representative of the overall Medicare-
eligible cohort.
Temporal trends of ULMCA PCI in the NCDR CathPCI
registry. Use of ULMCA PCI was rare at most centers (660
centers with 30 total procedures [“low” volume, 6
procedures per year]; 25 centers with 30 to 75 total
procedures [“moderate” volume, 6 to 15 procedures per
year]; and 8 centers with 75 ULMCA procedures over 5
years [“high” volume, 15 procedures per year]). The
proportion of patients with ULMCA disease treated with
ULMCA PCI at centers participating in the CathPCI
registry increased slightly throughout this interval (3.8% to
4.9%, p  0.0001) (Fig. 2A), and most ULMCA PCI cases
occurred in lower-urgency settings (Fig. 2B). DES were
used in a majority (81.8%) of lower-urgency procedures;
however, DES and BMS use was similar in high-urgency
procedures after 2006.
Overall ULMCA NCDR CathPCI cohort: in-hospital
outcomes. Overall, 95% of ULMCA patients survived to
hospital discharge. Stented ULMCA patients had a higher
unadjusted in-hospital mortality rate compared with non-
stented patients (13.1% vs. 4.6%, p  0.0001). In-hospital
mortality was associated with clinical urgency, with a greater
in-hospital mortality observed among patients with high
(45.1%) versus low (2.9%) clinical urgency and high (26.0%)
versus low (3.2%) pre-procedural logistic EuroSCORE.
Medicare-linked ULMCA PCI cohort: longitudinal
outcomes. Of the 2,765 patients with longitudinal follow-
up, 57.9% experienced a major adverse event by 30 months
(death: 42.7%; myocardial infarction: 8.2%; repeat revascu-
larization: 17.5%).
By 30 months, a similar unadjusted incidence of death
was observed across low-, moderate-, and high-volume
centers for both lower-urgency (35.4% vs. 36.4% vs. 33.9%,
p  0.2) and higher-urgency ULMCA PCI procedures
(65.1% vs. 73.2% vs. 59.9%, p  0.1). Composite events for
high-urgency patients were most common among centers
with the highest ULMCA PCI volume (low volume:
72.7%; moderate volume: 76.9%; high volume: 80.0%; p 
0.7)—a trend that reached significance among lower-
urgency patients (50.1%, 52.5%, and 60.3%, respectively;
p  0.0005).
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February 14, 2012:648–54 Left Main PCIThe 30-month outcomes stratified by clinical features are
presented in Figure 3. Patients with the highest unadjusted
ncidence of major adverse events by 30 months included
hose with high logistic EuroSCORE values (76.6% vs.
3.9% for low logistic EuroSCORE values, p  0.001),
igh clinical urgency (74.2% vs. 52.8% for low urgency, p 
.001) (Fig. 4), and bifurcation lesions (64.8% vs. 54.7% for
stial or mid-body, p  0.001) (Fig. 5).
The relative hazard of death by 30 months was lower
mong DES-treated versus BMS-treated patients both
efore and after adjustment by propensity weighting (39.6%
s. 52.7%; unadjusted HR: 0.60, 95% CI: 0.52 to 0.68;
djusted HR: 0.84, 95% CI: 0.73 to 0.96). However, no
isk-adjusted difference in composite events was observed
adjusted HR: 0.95, 95% CI: 0.84 to 1.06) (Fig. 6). The
elative risk of death and composite major adverse events
ssociated with the use of DES versus BMS was consistent
cross most of the subgroups examined (Figs. 3A and 3B).
iscussion
his analysis represents the first national report of outcomes
ith ULMCA PCI in the United States and the largest
Figure 2 NCDR CathPCI ULMCA Case Volume
Displays (A) time-trend in the unprotected left main coronary artery (ULMCA) percu
disease detection; and (B) changing profile of stent type for ULMCA PCI over time
stent(s); Qtr  quarter.eported experience of ULMCA PCI to date. It highlights imain findings. First, as of 2008, percutaneous treatment of
LMCA disease in the United States is uncommon and
enerally reserved for those with either a high burden of
oncardiac disease or emergent clinical presentations. Sec-
nd, elderly patients receiving ULMCA PCI are at high
isk for major adverse events following the procedure, with
0% dying within the first 3 years of follow-up. Finally, the
isk of adverse events appears related to certain procedural
haracteristics, including stent choice.
emporal trends in ULMCA PCI. In the United States,
he proportion of ULMCA patients treated with percuta-
eous revascularization remains low, but it is slowly increas-
ng. Through 2008, most centers performed 1 ULMCA
CI per month, although an increase in the volume of
ower-urgency procedures suggests increasing general accep-
ance of elective PCI for ULMCA at some centers. Con-
istent with international trends (10), DES remains the
redominant stent platform for lower urgency procedures in
he United States.
utcomes following PCI for ULMCA stenosis. In the
nited States, ULMCA PCI is performed primarily in
atients with a high burden of comorbidities and frequently
us coronary intervention (PCI) case volume as a percentage of overall ULMCA
ified by procedural urgency. BMS  bare-metal stent(s); DES  drug-elutingtaneo
, stratn those with high-urgency clinical presentations. In this
652 Brennan et al. JACC Vol. 59, No. 7, 2012
Left Main PCI February 14, 2012:648–54population, in-hospital mortality was substantially higher in
those with ULMCA disease who were treated percutane-
ously; however, this early risk is driven by those with
high-urgency, rather than lower-urgency, presentations.
Among ULMCA patients selected for PCI in the United
States, 30-month mortality is high (42.7%), with a predom-
inance of cardiovascular events. These findings are especially
notable when compared to the 10% mortality reported at 30
months in the MAIN-COMPARE (Korean Revasculariza-
tion for Unprotected Left Main Coronary Artery Stenosis:
Comparison of Percutaneous Coronary Angioplasty Versus
Surgical Revascularization) study (11), and the 4% mortality
reported at 1 year in the SYNTAX (Synergy Between PCI
With Taxus and Cardiac Surgery) trial (12). The increased
patient age, burden of comorbidities, and clinical acuity of
the NCDR ULMCA PCI cohort likely account for some
portion of the difference in outcomes, and the outcomes
reported here are more consistent with both early interna-
tional reporting of ULMCA PCI outcomes in nonoperable
patients (26.5% event-free survival at 9 months) (13) and
those reported in octogenarians undergoing ULMCA PCI
within the Canadian health system (56.7% event-free sur-
vival at 2 years) (14). These data highlight the need for
continued surveillance of ULMCA PCI in the United
States.
In addition to identifying several patient subgroups at
increased risk of adverse outcomes (i.e., patients with
bifurcation lesions), we have also identified important
trends in procedural technique. For example, single-stent
techniques, which have recently been associated with im-
proved outcomes (15), were less common in this ULMCA
PCI population (37.5%), but they were associated with
improved long-term outcomes as compared with 2-stent
techniques. Also, the use of intravascular ultrasound for
procedural guidance was much less common (18%) than
Figure 3
Comparative Effectiveness of BMS Versus DES
for Left Main Coronary Interventions
in Select Patient Subgroups
Displays (A) 30-month death (hazard ratio [HR] 1.0 favors drug-eluting stent
[DES]); and (B) 30-month death, myocardial infarction (MI), or repeat revascu-
larization (Revasc) (HR 1.0 favors DES). BMS  bare-metal stent(s).reported elsewhere (e.g., 78% in the MAIN-COMPAREregistry) (16). In this cohort, intravascular ultrasound use
was associated with a lower unadjusted incidence of both
major adverse events (51% vs. 59%) and death (35% vs.
44%), adding to the growing body of nonrandomized
literature supporting its use during ULMCA stenting (17).
Finally, our results are consistent with prior reports
suggesting that DES are superior to BMS for the treatment
of left main lesions (18). Here, DES were associated with
improved survival when compared with BMS, but the
mechanism by which stent type affects the risk of death in
this population remains unclear.
Study limitations. These data represent the largest-ever
experience with percutaneous revascularization of ULMCA
disease, and the first-ever report of the U.S. national
experience with these procedures; however, several limita-
tions are notable. First, the reporting of diagnostic-only
procedures is voluntary in most health systems and is
believed to be less reliable at some centers. Second, the
NCDR data does not allow a direct comparison of outcomes
with percutaneous, surgical, and medical treatment strate-
gies. Third, the longitudinal cohort is drawn from a Medi-
care FFS subgroup of the overall population in the United
States; however, this cohort is highly representative of
elderly patients undergoing percutaneous ULMCA revas-
cularization in the United States. Fourth, outcomes are
assessed using inpatient claims data and, therefore, are
subject to inherent reporting errors and detection biases. For
example, the exclusion of outpatient “observational” hospital
visits potentially resulted in an underestimation of the
incidence of repeat revascularization. Fifth, although 66% of
the deaths with an attributable “cause” occurred in-hospital,
the use of Medicare claims to ascertain the true “cause of
death” is imprecise and should be viewed simply as hypoth-
esis generating. Finally, the outcome comparison for pa-
tients treated with DES versus BMS is subject to unmea-
sured biases inherent to the device selection, which may
favor DES (3). A comparison to clinical trial data is not
Figure 4 Unadjusted Cumulative Incidence
by Procedural Urgency
Unadjusted cumulative incidence of death, MI, or repeat
Revasc, stratified by procedural urgency. Abbreviations as in Figure 3.
653JACC Vol. 59, No. 7, 2012 Brennan et al.
February 14, 2012:648–54 Left Main PCIFigure 5 Unadjusted Cumulative Incidence by Lesion Location
Unadjusted cumulative incidence of death, MI, or repeat Revasc, stratified by left main lesion location. Note: The high incidence of death/MI/revascularization at the
beginning of follow-up (t  0) reflects a high incidence of in-hospital adverse events among high-urgency patients. EF  ejection fraction; IDDM  insulin-dependent dia-
betes mellitus; IVUS  intravascular ultrasound; KM  Kaplan-Meier; LM  left main; NIDDM  noninsulin-dependent diabetes mellitus; other abbreviations as in
Figure 3.
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Left Main PCI February 14, 2012:648–54possible in this setting, as no prior clinical trials have
randomized ULMCA patients to DES versus BMS.
Implications for future research. These results emphasize
the need for a well-powered randomized clinical trial
examining the safety and effectiveness of percutaneous
revascularization in patients with ULMCA disease, with
attention to the generalizability of U.S. patients recruited
for trial participation and best practices in procedural
techniques for revascularization.
Conclusions
ULMCA PCI remains a relatively uncommon procedure at
most U.S. centers and is primarily reserved for those at high
risk for coronary artery bypass graft surgery. Poor outcomes
following percutaneous revascularization in elderly UL-
MCA patients are common and are likely influenced by
both patient and procedural characteristics.
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